论文部分内容阅读
去整合素-金属蛋白酶17(adisintegrin and metalloproteinase17,ADAM17)是近年来发现的金属蛋白酶解聚素(adisintegrinand metalloproteinase,ADAMs)家族成员之一,参与肿瘤发生发展的重要过程。去整合素-金属蛋白酶17(ADAM17)又称为肿瘤坏死因子转换酶(TACE),因此除了具有解聚素和金属蛋白酶的活性,还可以将没有活性的肿瘤坏死因子(TNF-α)从细胞膜上切割下来,并与其受体相结合,从而激活TNF-α下游的EGFR信号传导,此外还可以激活多条信号传导途径如Notch传导通路等,进而影响肿瘤细胞的粘附、凋亡、转移、增殖等生物学行为。纵观ADAM17的研究,在多种恶性肿瘤中呈高表达状态,且这种高表达状态与肿瘤侵润程度及转移情况相关。随着人们对ADAM17基础科学的研究不断深入,ADAM17的临床应用前景也正被不断开发,鉴于其在多种恶性肿瘤组织中高表达的情况,可将其作为许多肿瘤的诊断标志物、及判断其转移和预后情况。靶向药物的研究给恶性肿瘤患者带来了新的福音,利用EGFR为研究扳机点成功研制出许多靶向药物,在EGFR的配体释放环节,ADAM17尤为重要。本文总结了ADAM17在恶性肿瘤发展中的作用及其机制,对其在癌症治疗的应用前景进行展望。
Adisintegrin and metalloproteinase17 (ADAM17) is one of the members of the family of ADAMs found in recent years and is involved in the development of tumors. Integrin-metalloproteinase 17 (ADAM17), also known as Tumor Necrosis Factor-converting enzyme (TACE), can also remove inactive tumor necrosis factor (TNF-α) from the cell membrane And then combined with its receptor to activate EGFR signaling downstream of TNF-α. In addition, it can activate a number of signal transduction pathways such as Notch transduction pathway, and then affect the adhesion, apoptosis, metastasis, Proliferation and other biological behavior. Throughout ADAM17 study, in a variety of malignant tumors was highly expressed state, and this high expression state and tumor invasion and metastasis. With the continuous research on the basic science of ADAM17, the clinical application prospect of ADAM17 is also being continuously developed. Because of its high expression in many malignant tumors, it can be used as a diagnostic marker for many tumors and to judge its Metastasis and prognosis. Targeted drug research has brought a new gospel to patients with malignant tumors. The successful development of many targeted drugs using EGFR as a trigger point in the study has shown that ADAM17 is particularly important in the ligand release of EGFR. This article summarizes the role of ADAM17 in the development of malignant tumors and its mechanism, and its prospect in the application of cancer treatment.